MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Fürstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, Bittenbring J, Hebart H, Schöttker B, Illert AL, Graeven U, Stoltefuß A, Heinrich B, Eckert R, Fink A, Stumpf J, Fischer K, Al-Sawaf O, Simon F, Kleinert F, Weiss J, Kreuzer KA, Schilhabel A, Brüggemann M, Langerbeins P, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P

Open source

DOI: 10.1182/blood.2024026685
Published: 2025 Mar 20
Container: Blood
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2024026685,
  title = {MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.},
  author = {Fürstenau M and Robrecht S and Schneider C and Tausch E and Giza A and Ritgen M and Bittenbring J and Hebart H and Schöttker B and Illert AL and Graeven U and Stoltefuß A and Heinrich B and Eckert R and Fink A and Stumpf J and Fischer K and Al-Sawaf O and Simon F and Kleinert F and Weiss J and Kreuzer KA and Schilhabel A and Brüggemann M and Langerbeins P and Stilgenbauer S and Eichhorst B and Hallek M and Cramer P},
  year = {2025},
  journal = {Blood},
  doi = {10.1182/blood.2024026685},
  url = {https://doi.org/10.1182/blood.2024026685}
}

RIS

TY  - JOUR
TI  - MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
AU  - Fürstenau M
AU  - Robrecht S
AU  - Schneider C
AU  - Tausch E
AU  - Giza A
AU  - Ritgen M
AU  - Bittenbring J
AU  - Hebart H
AU  - Schöttker B
AU  - Illert AL
AU  - Graeven U
AU  - Stoltefuß A
AU  - Heinrich B
AU  - Eckert R
AU  - Fink A
AU  - Stumpf J
AU  - Fischer K
AU  - Al-Sawaf O
AU  - Simon F
AU  - Kleinert F
AU  - Weiss J
AU  - Kreuzer KA
AU  - Schilhabel A
AU  - Brüggemann M
AU  - Langerbeins P
AU  - Stilgenbauer S
AU  - Eichhorst B
AU  - Hallek M
AU  - Cramer P
PY  - 2025
JO  - Blood
DO  - 10.1182/blood.2024026685
UR  - https://doi.org/10.1182/blood.2024026685
ER  -

APA

M, F., S, R., C, S., E, T., A, G., M, R., J, B., H, H., B, S., AL, I., U, G., A, S., B, H., R, E., A, F., J, S., K, F., O, A., F, S., F, K., J, W., KA, K., A, S., M, B., P, L., S, S., B, E., M, H., & P, C. (2025). MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.. Blood. https://doi.org/10.1182/blood.2024026685

Source records

pubmed · retrieved 2026-09-27T10:15:03.424Z